
-
May 17, 2024Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
Gembloux, Belgium – May 17, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO).
Read More -
May 10, 2024Full-Life Technologies will showcase preclinical data of its NTSR1-targeted RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting
Shanghai, China, and Heidelberg, Germany – May 10, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that it will present preclinical data of FL-091 (a NTSR1-targeted RDC program) in an oral presentation at the 2024 SNMMI.
Read More -
Apr 11, 2024Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
Full-Life Technologies announced that the company has presented the preclinical data of 225Ac-FL-020 (a PSMA-targeted RDC program) at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Read More -
Mar 26, 2024Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction
Gembloux, Belgium – Mar. 26, 2024 – Full-Life Technologies (“Full-Life”), today announced the recent achievement of its subsidiary “Full-Life Technology Europe” has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control (“FANC”).
Read More -
Mar 11, 2024Full-Life Technologies will present preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
Shanghai, China, and Heidelberg, Germany – Mar. 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that preclinical data of 225Ac-FL-020 (a PSMA-targeted RDC program) will be presented in a Poster Session at the AACR (American Association for Cancer Research) Annual Meeting 2024.
Read More